Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients

Trial Profile

Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Gemcitabine (Primary) ; Romidepsin (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms FIL-GEMRO
  • Most Recent Events

    • 07 Feb 2018 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 28 Jan 2016 Planned End Date changed from 1 Sep 2015 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
    • 08 Dec 2015 Status changed from recruiting to active, no longer recruiting as results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top